Announced
Completed
Synopsis
Everlife, a provider of diagnostic products and solutions to clinical and scientific laboratories, led a $27m Series A funding round in AUM Biosciences, an oncology-focused biotechnology company that aims to accelerate the development of innovative, affordable medicines for patients, with participation from SPRIM Global Investments. AUM will use the funds for the clinical development of its portfolio with immediate initiation of two Phase II programmes for MNK and TRK inhibitors.
Principals
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.